FARMINGDALE, N.Y., July 11, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced its participation in SpineWeek 2012, which recently took place in Amsterdam, Netherlands. This is the third meeting in the series, which commenced in 2004.
SpineWeek takes place every four years and synchronizes the annual meetings of leading scientific societies, focused on disorders of the spine, in one location, simplifying logistics while maximizing the exchange of information generated from research and clinical practice. Clinician attendance was greater than 2,600 individuals, including many recognized leaders in the field, who attended from all corners of the globe.
A key component of SpineWeek, sponsored by the medical device industry, is a major exhibition of innovative products and services used by spine surgeons worldwide. This unique forum provided a showcase for the Company's innovative BoneScalpel™ Ultrasonic Bone Cutting System, including some recent line extensions, and provided an opportunity for more than 100 clinicians in attendance to participate in "hands on" demonstrations of this important new technology. More than 75 of these physicians requested presentations and/or evaluations at their respective hospitals. In addition, multiple existing users of the technology visited the exhibit to share their experiences with clinical use of the Product, commenting on the precise nature of the bone cuts, minimal bone loss, reduced bleeding, reduction in procedure time and a general feeling that BoneScalpel provided an extra measure of safety.
As stated by noted German neurosurgeon, Daniel Rosenthal, "I use the BoneScalpel in arthrectomy or vertebrectomy, and to decompress the foramina. In my opinion, it replaces the saw or drill in spine surgery."
The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps. To date, reported uses of the Product in spine surgery include laminectomy, laminotomy, laminoplasty, corpectomy, spinal deformity, foraminotomy, facetectomy and other procedures performed by orthopedic and neuro surgeons.
"We were very pleased to participate in this singular event that brings together researchers and thought leaders from around the globe that specialize in correcting spinal disorders," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Exhibiting our state-of-the-art technology at this prestigious gathering further demonstrates our commitment to providing products to the medical community that can directly impact patient outcomes."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations ContactsMisonix Contact:
Lytham Partners, LLCRichard Zaremba
Robert Blum, Joe Dorame, Joe Diaz631-694-9555
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved